Lynx Capital Group’s Pfizer PFE Stock Holding History

Lynx Capital Group’s Portfolio PFE Stock Details PFE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-70,578	Closed	-$1.96M	–	81
2024 Q1	$1.96M	Buy	70,578 +23,242	+49%	+$645K	1.32%	39
2023 Q4	$1.36M	Buy	+47,336	New	+$1.43M	0.99%	45

Other funds holding PFE

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return

Lynx Capital Group's PFE Position: Q2 2024 in Review

Lynx Capital Group sold out of Pfizer (PFE) in Q2 2024, closing a stake of 70,578 shares — an estimated $1.96M sold.

Lynx Capital Group first reported a position in PFE in Q4 2023 and held it in 2 quarters. The position peaked at $1.96M in Q1 2024. 2,876 funds tracked by Wall St. Rank hold PFE as of Q2 2024.

Lynx Capital Group reported no remaining Pfizer position as of Q2 2024 after selling out during the quarter.
Lynx Capital Group sold 70,578 Pfizer shares in Q2 2024, an estimated $1.96M.
Lynx Capital Group first reported a position in Pfizer in Q4 2023 and held it in 2 quarters.
Lynx Capital Group's Pfizer position peaked at $1.96M in Q1 2024.
2,876 funds tracked by Wall St. Rank held Pfizer as of Q2 2024.

Based on Lynx Capital Group's 13F filing for Q2 2024, filed 10 Aug 2026.